Promising candidates in clinical trials against multidrug-resistant tuberculosis (MDR-TB) based on natural products

Fitoterapia

Volumn 80, Issue 8, 2009, Pages 453-460

  de Souza, Marcus Vinícius Nora ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Drugs; Natural products; Tuberculosis

Indexed keywords

AMIDE; AMIKACIN; BETA SULFONYLCARBOXAMIDE; CAPRAZAMYCIN; CAPREOMYCIN; CAPURAMYCIN; CERULENIN; CYCLOSERINE; ENZYME INHIBITOR; ERYTHROMYCIN; FAS 20013; FATTY ACID SYNTHASE; KANAMYCIN; KANAMYCIN A; NATURAL PRODUCT; PACIDAMYCIN; PLEUROMUTILIN; RIFABUTIN; RIFAMPICIN; RIFAMPICIN DERIVATIVE; RIFAMYCIN; RIFAMYCIN B; RIFAPENTINE; STREPTOMYCIN; THIOLACTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ALLERGY; ANTIBACTERIAL ACTIVITY; ATYPICAL MYCOBACTERIOSIS; BACTERIAL STRAIN; CLINICAL TRIAL; DISEASE CONTROL; DRUG ADSORPTION; DRUG DESIGN; DRUG DETERMINATION; DRUG INHIBITION; DRUG MECHANISM; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPHILICITY; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FUNGAL PROTEINS; FUNGI; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 70349823195     PISSN: 0367326X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fitote.2009.07.010     Document Type: Review

References (36)

1. http://www.who.int/topics/tuberculosis/en/. Accessed August 27, 2009.
2. Souza M.V.N. Current status and future prospects for new therapies for pulmonary tuberculosis. Curr Opin Pulm Med 12 (2006) 167-171
3. Newman D.J., Cragg G.M., and Snader K.M. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66 (2003) 1022-1037
4. Kingston W. Streptomycin, Schatz v. Waksman, and the balance of credit for discovery. J Hist Med Allied Sci 59 (2004) 441-462
5. Souza M.V.N. Promising drugs against tuberculosis. Recent Pat Antiinfect Drug Discov 1 (2006) 33-44
6. Floss H.G., and Yu T.W. Rifamycin mode of action, resistance, and biosynthesis. Chem Rev 105 (2005) 621-632
7. Souza M.V.N. Marine natural products against tuberculosis. TSWJ 6 (2006) 847-861
8. Souza M.V.N. Plants and fungal products with activity against tuberculosis. TSWJ 5 (2005) 609-628
9. Copp B.R., and Pearce A.N. Natural product growth inhibitors of Mycobacterium tuberculosis. Nat Prod Rep 24 (2007) 278-297
10. Guido F., Pauli G.F., Case R.J., Inui T., Wang Y., Cho S., et al. New perspectives on natural products in TB drug research. Life Sci 78 (2005) 485-499
11. http://www.iom.edu/Object.File/Master/59/970/Ginsberg.pdf.
12. Kavanagh F., Hervey A.W.J., and Robbins W.J. Antibiotic substances from basidiomycetes. Proc Natl Acad Sci USA 37 (1951) 570-574
13. Anchel M. Chemical studies with pleuromutilin. JBC 199 (1952) 133-140
14. Arigoni D.G. Structure of a new type of terpene. Chim Ital 92 (1962) 884-901
15. Birch A.J., Cameron D.W., Holzapfel C.W., and Rihards R.W. The structure and some aspects of the biosynthesis of pleuromutilin. Chem Ind (1963) 374-375
16. Birch A.J., Holzapfel C.W., and Rickardsm R.W. The structure and some aspects of the biosynthesis of pleuromutilin. Tetrahedron Suppl 8 Part II (1966) 359-387
17. Springer D.M., Goodrich J.T., Luh B.Y., Bronson J.J., Gao Q., Huang S., et al. Antibacterial pleuromutilin derivatives based on alternate core structures: Arigoni and Birch chemistry revisited. LDDD 5 (2008) 327-331
18. Szybalski W. Genetic studies on microbial cross resistance to toxic agents: IV. Cross resistance of Bacillus megaterium to forty-four microbial drugs. Appl Microbiol 2 (1954) 57-63
19. Szybalski W. Genetic studies on microbial cross resistance to toxic agents. Antibiot Chemother 3 (1953) 1095-1103
20. Arigoni D. Some studies in the biosynthesis of terpenes and related compounds. Pure Appl Chem 17 (1968) 331-348
21. Riedl K. Studies on pleuromutilin and some of its derivatives. J Antibiot 29 (1976) 132-139
22. Egger H., and Reinshagen H. New pleuromutilin derivatives with enhanced antimicrobial activity. I. Synthesis. J Antibiot 29 (1976) 915-922
23. Egger H., and Reinshagen H. New pleuromutilin derivatives with enhanced antimicrobial activity.II. Structure-activity correlations. J Antibiot 29 (1976) 923-927
24. A. Hudson, T. Imamura, W. Gutteride, T. Kanyok and P. Nunn http://www.who.int/tdr/publications/publications/antitb_drug.htm. Accessed August 27, 2009.
25. Falzari K., Zhu Z., Pan D., Liu H., Hongmanee P., and Franzblau S.G. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 49 (2005) 1447-1454
26. Souza M.V.N., Ferreira M., Pinheiro A.C., Saraiva M.F., Almeida M.V., and Valle M.S. Synthesis and biological aspects of mycolic acids: an important target against Mycobacterium tuberculosis. TSWJ 8 (2008) 720-751
27. Boojamra C.G., Lemoine R.C., Blais J.V., Vernier N.G., Stein K.A., Magon A., et al. Synthetic dihydropacidamycin antibiotics: a modified spectrum of activity for the pacidamycin class. Bioorg Med Chem Lett 13 (2003) 3305-3309
28. Igarashi M., Takahashi Y., Shitara T., Nakamura H., Naganawa H., Miyake T., and Akamatsu Y. Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp.: II. Structure elucidation of caprazamycins. J Antibiot 58 (2005) 327-337
29. Yamaguchi H., Sato S., Yoshida S., Takada K., Itoh M., Seto H., et al. Capuramycin, a new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. J Antibiot 39 (1986) 1047-1053
30. Koga T., Fukuoka T., Doi N., Harasaki T., Inoue H., Hotoda H., et al. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J Antibiot Chemother 54 (2004) 755-760
31. Oishi H., Noto S., Sasaki H., Suzuki K., Hayashi T., Okazaki H., et al. Thiolactomycin, a new antibiotic. J Antibiot 35 (1982) 391-395
32. Sano Y., Nomura S., Kamio Y., Omura S., and Hata T. Studies on cerulenin. III. Isolation and physico-chemical properties of cerulenin. J Antibiot Ser A 20 (1967) 344-348
33. D'Agnolo G., Rosenfeld I.S., Awaya J., Omura S., and Vagelos P.R. Inhibition of fatty acid synthesis by the antibiotic cerulenin. Specific inactivation of beta-ketoacyl-acyl carrier protein synthetase. Biochim Biophys Acta 326 (1973) 155-156
34. Omura S. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev 40 (1976) 681-697
35. Mani N.S., and Townsend C.A.A. A concise synthesis of (+)-cerulenin from a chiral oxiranyllithium. J Org Chem 62 (1997) 636-640
36. Parrish N.M., Kuhajda F.P., Heine H.S., Bishal W.R., and Dick J.D. Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. J Antimicrob Chemother 43 (1999) 219-226